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RESULTS: Final analysis included 9337 patients. Mean age of patients was 41.75 
10.11 years. Sixty nine percent patients were males. Treatment success rate was
77.5% (n  7240). Among 7240 successfully treated patients, 5319 patients cured
while 1921 completed their treatment. Among 22.5% (n2097) unsuccessfully
treated patients, 503 died, 502 defaulted, 369 transferred out and 723 were on
treatment continued. In multivariate analysis new TB infection (OR1.315,
p-value0.001) was the only factor associated with successful treatment outcome.
Whereas extra pulmonary TB (OR0.541, p-value0.001), pulmonary  extra pul-
monary TB (O 0.523, p-value0.001), urban area (OR0.889, p-value0.030),
smoking (OR0.890, p-value0.030), alcohol consumption (OR0.807,
p-value0.011) intravenous drug use (OR0.676, p-value0.001) and employment
(OR0.507, p-value0.001) had statistically significant negative association with
successful treatment outcome. CONCLUSIONS: Although more than three fourth
(77.5%) patients were treated successfully but the treatment success rate is still
behind the WHO target of 85%. In future more attention should be paid to patients
with extra pulmonary TB, belonging to urban area, smokers, alcohol consumers,
intravenous drug users and employees.
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OBJECTIVES: An unmet need remains for new effective treatments and/or man-
agement strategies for influenza in high-risk groups. Complications and mortality
rates might differ among high risk groups, such as those who are aged 65 years and
older compared with those with different chronic underlying medical conditions.
METHODS: A literature review was performed using electronic database keyword
searches, specific inclusion and exclusion criteria, quality rating of the reviewed
full-text articles, and abstraction of data to evaluate the published evidence on the
incidence, complication rates, and health service use associated with clinical in-
fluenza in different high-risk groups. RESULTS: Key findings for incidence rates of
clinical influenza were that these rates are similar among people with chronic
cardiovascular or respiratory comorbidity but may be higher in those with alloge-
neic stem cell transplants compared to those with autologous transplants. Rates of
hospitalization and/or pneumonia or lower respiratory tract infection for those
with chronic conditions or those who are immunocompromised (2.9% to 80%) are
significantly higher than those in people over age 65 but without additional high-
risk factors (0%). A person who is hospitalized and has a laboratory-confirmed
influenza diagnosis has a probability of intensive care unit admission of between
11.8% and 28.6% and of death of between 2.9% and 14.3%. Most of the studies of
hospitalized patients did not present outcomes data separately by high-risk group.
In addition, the rates and outcomes of influenza complications in all high-risk
groups are variable from year to year depending on the circulating influenza
viruses. CONCLUSIONS: These findings indicate that the burden of influenza may
vary by high-risk group although there are only limited data available to quantify
these differences. This information could be used to evaluate new therapies, in-
cluding better influenza vaccines, chemoprophylaxis, and/or treatment strategies
for different high-risk groups.
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OBJECTIVES: In the UK, PPV23 has been recommended in the elderly (aged 65 and
over) and at-risk adults. In 2007, PCV was introduced in children, leading to a
decrease in invasive pneumococcal disease (IPD) incidence associated with the PCV
serotypes not only in vaccinated children but also in unvaccinated adults. The use
of PCV13 in adults is currently under consideration pending data on efficacy in this
population. This study aimed to assess the BI of PPV23 vs. NoVac or PCV13 in the
UK, accounting for recent epidemiological changes. METHODS: The model was
adapted from a previous population-based Markov model, consisting of five health
states: no PD, IPD, NBPP (non-bacteraemic pneumococcal pneumonia), post-men-
ingitis sequelae and death. Epidemiology and costs were estimated from UK
sources. The analysis tracked cohorts of vaccinated and unvaccinated population
between 2012 and 2016. Four scenarios were tested and equal market shares were
assumed between PCV13 and PPV23. RESULTS: Over the study period, PPV23 vac-
cination led to a reduction in the number of IPD cases, ranging from 1,773 to 1,957
(vs. NoVac) or from -154 to 617 (vs. PCV13). The reduction in the number of NBPP
cases ranged from -2 to 23,969 (vs. NoVac) or from -11,984 to 0 (vs. PCV13). When
compared to NoVac, PPV23 vaccination was associated with a total cost of £63
million, whereas introducing PCV13 required an additional funds of £54 million.
The net budget impact ranged between £36 million and £59 million (vs. NoVac) or
between -£56 million and -£47 million (vs. PCV13). CONCLUSIONS: The model sug-
gests that vaccinating with PPV23 significantly reduces the burden of pneumococ-
cal disease despite the epidemiological changes. Introducing PCV13 is likely to
impose a significant impact on the health care budget and assumptions around the
efficacy of PCV13 are a substantial source of uncertainty in its public health bene-
fits.
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OBJECTIVES: The gradual increase of persons living with HIV, mainly due to the
reduced mortality achieved with effective antiretroviral therapies, calls for in-
creased rationality and awareness in health resources consumption also during
the early illness phases. Aim of this work is the estimation of the budget impact
related to the variation in backbone prescribing trends in naïve patients.
METHODS:Target population is the number of patients starting antiretroviral ther-
apy each year, according to the Italian HIV surveillance registry, excluding patients
receiving non-authorized or non-recommended regimens. We modeled 3-year
mortality and durability rates on a dynamic cohort, basing on international litera-
ture. Current Italian market shares of triple regimens containing first-choice back-
bones (TDF/FTC, ABC/3TC, TDF3TC, AZT/3TC) are compared to an hypothetical
scenario in which all patients eligible to ABC/3TC treatment (HLA-B*5701 negative
patients with 100,000 HIVRNA copies/mL) start a regimen containing this back-
bone as first line strategy. Annual cost for each regimen comprises drugs acquisi-
tion under hospital pricing rules, and monitoring exams and preventive tests, val-
ued basing on regional reimbursement tariffs. RESULTS: According to current
prescribing trends, in the next three years about 13,000 patients starting HIV ther-
apy will receive TDF/FTC (83% of the target population), and minor portions other
regimens (9% ABC/3TC, 8% AZT/3TC). Patients that would be eligible to ABC/3TC are
about six thousand more than those presently treated with this backbone, leading
to a saving of 3.1 million Euro over the three-year period. Sensitivity analyses on
different hypotheses of “third” drug market shares indicate savings ranging from
720 thousand to 3.9 million Euro. Most of this amount is due to reduced acquisition
costs and, secondarily, to lower monitoring needs. CONCLUSIONS: Where patient
features don’t force the choice of the backbone, ABC/3TC prescription may induce
substantial savings, allowing the release of resources needed to manage more
complicated/advanced cases.
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OBJECTIVES: To determine the economic impact of three different hospital-ac-
quired infections (HAI) in mechanically ventilated (MV) patients in intensive care
unit (ICU) and assess the attributable costs, hospital length of stay (LOS) and inpa-
tient mortality in a U.S. hospital database. METHODS: A U.S. retrospective cohort
study was undertaken using hospital database from the Premier Perspective of
adults (18 years old) with a stay  48h in 2007. Three HAIs were followed: blood-
stream infection (BSI), surgical site infection (SSI), and hospital-acquired pneumo-
nia (HAP) including ventilator-associated pneumonia (VAP). From a previous anal-
ysis, MV device was identified as an impactful risk factor in ICU showing higher
prevalence for HAP/VAP and BSI. Case subjects were defined as patients with HAI
event among the MV population. Economic criteria were defined as hospital LOS,
inpatient mortality and inpatient costs. RESULTS: Out of 463,491 patients meeting
the entry criteria, 101,540 (21.9%) received a MV setting. Focusing on this MV pop-
ulation, 51,683 (50.9%) patients developed HAI: HAP/VAP: 33.2%, BSI: 29.4%, and SSI:
2.3%. Compared with control, patients with HAI were more elderly (54% vs. 49%),
were more likely to be admitted via emergency room (86% vs. 78%), presented with
more severe illnesses, higher risk of mortality, and with central catheter place-
ments (67% vs. 39%). The inpatient mortality rate and mean LOS were higher in
patients with HAI (32% vs. 18% and 21.222.3 vs. 11.811.4 days, respectively).
Mean total costs were higher in HAI patients (56,751US$) compared to non-HAI
patients (34,032US$). In MV population, HAI patients had higher consumptions of
inpatient resources and inpatient mortality: extended LOS equal to 9.4 days, in-
creased total inpatient costs equal to 22,719US$ and extended mortality of 14%.
CONCLUSIONS: These data illustrate the significant economic burden and mortal-
ity of HAI in a category of at-risk population on MV and request the needs for
intervention.
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Pneumococcal diseases (PD), such as bacteremia, meningitis and pneumonia, are
associated with substantial burden in adults (50 years). Moreover, adults with
underlying chronic conditions (i.e., vascular, metabolic, or respiratory diseases)
have shown to have 3–6 times higher risk of PD compared with their healthy
controls. These people at higher risk will likely benefit most of PCV13 vaccination in
the new adult indication. OBJECTIVES: To estimate the expected 5-year economic
impact of targeted PCV13 vaccination compared to no vaccination in Finnish adults
(50 years) at higher risk for PD. METHODS: A budget impact model applying a
modified Markov-type structure was developed to predict the impact of PCV13
vaccination in terms of costs and PD events avoided. The model was built as a
dynamic open-cohort model to allow the annual evolution of the size of prevalent
target population with considered PCV13 indications. The results of model were
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